文献速递水电解质与酸碱

SGLT2抑制剂恩格列净治疗慢性抗利尿不当综合征:随机双盲安慰剂对照交叉试验

Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial.
PubMed 文献 · J Am Soc Nephrol · 2022-11-17

该随机双盲安慰剂对照交叉试验比较恩格列净25 mg/d与安慰剂各治疗4周对慢性抗利尿不当综合征相关低钠血症门诊患者的作用,14例患者完成试验。恩格列净组中位血钠升至134 mmol/L而安慰剂组无升高,血钠升高4.1 mmol/L(95%CI 1.7至6.5;P=0.004)。恩格列净耐受良好,无严重不良事件。

要点

  • 恩格列净25 mg/d治疗4周使慢性SIAD相关低钠血症患者中位血钠由131升至134 mmol/L。
  • 安慰剂组中位血钠无升高(130 mmol/L),两组血钠差为4.1 mmol/L(95%CI 1.7至6.5;P=0.004)。
  • 探索性分析示MoCA评分增加1.16(95%CI 0.05至2.26),治疗耐受良好,无严重不良事件。

核心结论

  • 恩格列净是慢性SIAD相关低钠血症有前景的新治疗选择,可能改善神经认知功能,需更大规模研究证实所观察到的疗效。

研究设计与样本

  • 随机、双盲、安慰剂对照交叉试验,比较恩格列净25 mg/d与安慰剂各治疗4周,纳入慢性SIAD相关低钠血症门诊患者,14例完成试验。

主要发现

  • 14例完成试验,女性占50%,中位年龄72岁(IQR 65至77),基线中位血钠131 mmol/L(IQR 130至132)。
  • 恩格列净治疗后中位血钠升至134 mmol/L(IQR 132至136),安慰剂组无升高(130 mmol/L;IQR 128至132)。
  • 两组血钠差异为升高4.1 mmol/L(95%CI 1.7至6.5;P=0.004)。
  • 探索性分析显示恩格列净使MoCA评分增加1.16(95%CI 0.05至2.26)。
  • 治疗耐受良好,未报告严重不良事件。

临床怎么用

  • 原文结论认为恩格列净是慢性SIAD相关低钠血症有前景的新治疗选择,可能改善神经认知功能,需更大规模研究证实。

局限性

  • 原文结论指出需更大规模研究证实所观察到的疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The syndrome of inappropriate antidiuresis (SIAD) is characterized by a reduction of free water excretion with consecutive hypotonic hyponatremia and is therefore challenging to treat. The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin promotes osmotic diuresis via urinary glucose excretion, likely leading to increased electrolyte free water clearance. METHODS: In this randomized, double-blind, placebo-controlled, crossover trial, we compared 4-week treatment with empagliflozin 25 mg/d to placebo in outpatients with chronic SIAD-induced hyponatremia. At baseline and after both treatment cycles, patients underwent different assessments including neurocognitive testing (Montreal Cognitive Assessment [MoCA]). The primary end point was the difference in serum sodium levels between treatments. RESULTS: Fourteen patients, 50% female, with a median age of 72 years (interquartile range [IQR], 65-77), completed the trial. Median serum sodium level at baseline was 131 mmol/L (IQR, 130-132). After treatment with empagliflozin, median serum sodium level rose to 134 mmol/L (IQR, 132-136), whereas no increase was seen with placebo (130 mmol/L; IQR, 128-132), corresponding to a serum sodium increase of 4.1 mmol/L (95% confidence interval [CI], 1.7 to 6.5; P =0.004). Exploratory analyses showed that treatment with empagliflozin led to improved neurocognitive function with an increase of 1.16 (95% CI, 0.05 to 2.26) in the MoCA score. Treatment was well tolerated; no serious adverse events were reported. CONCLUSION: The SGLT2 inhibitor empagliflozin is a promising new treatment option for chronic SIAD-induced hyponatremia, possibly improving neurocognitive function. Larger studies are needed to confirm the observed treatment effects. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov NCT03202667. PODCAST: This article contains a podcast at.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Refardt J, Imber C, Nobbenhuis R, et al. Treatment Effect of the SGLT2 Inhibitor Empagliflozin on Chronic Syndrome of Inappropriate Antidiuresis: Results of a Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. J Am Soc Nephrol. 2022. PMID: 36396331. doi:10.1681/ASN.2022050623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。